A | SK | HUMAN NECESSITIES |
A61 | USK | HEALTH; AMUSEMENT |
A61 | KL | MEDICAL OR VETERINARY SCIENCE; HYGIENE |
A61P | UKL | THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS [7] |
A61P 1/00 | HGR | Drugs for disorders of the alimentary tract or the digestive system [7] |
A61P 1/02 | UGR1 | . | Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis [7] |
|
A61P 1/04 | UGR1 | . | for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants [7] |
|
A61P 1/06 | UGR1 | . | Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia [7] |
|
A61P 1/08 | UGR1 | . | for nausea, cinetosis or vertigo; Antiemetics [7] |
|
A61P 1/10 | UGR1 | |
A61P 1/12 | UGR1 | |
A61P 1/14 | UGR1 | . | Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents [7] |
|
A61P 1/16 | UGR1 | . | for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics [7] |
|
A61P 1/18 | UGR1 | . | for pancreatic disorders, e.g. pancreatic enzymes [7] |
|
A61P 3/00 | HGR | Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P 7/00) [7] |
A61P 3/02 | UGR1 | . | Nutrients, e.g. vitamins, minerals [7] |
|
A61P 3/04 | UGR1 | . | Anorexiants; Antiobesity agents [7] |
|
A61P 3/06 | UGR1 | |
A61P 3/08 | UGR1 | . | for glucose homeostasis (pancreatic hormones A61P 5/48) [7] |
|
A61P 3/10 | UGR2 | . . | for hyperglycaemia, e.g. antidiabetics [7] |
|
A61P 3/12 | UGR1 | . | for electrolyte homeostasis [7] |
|
A61P 3/14 | UGR2 | |
A61P 5/00 | HGR | Drugs for disorders of the endocrine system [7] |
A61P 5/02 | UGR1 | . | of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin [7] |
|
A61P 5/04 | UGR2 | . . | for decreasing, blocking or antagonising the activity of the hypothalamic hormones [7] |
|
A61P 5/06 | UGR1 | . | of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH [7] |
|
A61P 5/08 | UGR2 | . . | for decreasing, blocking or antagonising the activity of the anterior pituitary hormones [7] |
|
A61P 5/10 | UGR1 | . | of the posterior pituitary hormones, e.g. oxytocin, ADH [7] |
|
A61P 5/12 | UGR2 | . . | for decreasing, blocking or antagonising the activity of the posterior pituitary hormones [7] |
|
A61P 5/14 | UGR1 | . | of the thyroid hormones, e.g. T3, T4 [7] |
|
A61P 5/16 | UGR2 | . . | for decreasing, blocking or antagonising the activity of the thyroid hormones [7] |
|
A61P 5/18 | UGR1 | . | of the parathyroid hormones [7] |
|
A61P 5/20 | UGR2 | . . | for decreasing, blocking or antagonising the activity of PTH [7] |
|
A61P 5/22 | UGR2 | . . | for decreasing, blocking or antagonising the activity of calcitonin [7] |
|
A61P 5/24 | UGR1 | |
A61P 5/26 | UGR2 | |
A61P 5/28 | UGR2 | |
A61P 5/30 | UGR2 | |
A61P 5/32 | UGR2 | |
A61P 5/34 | UGR2 | |
A61P 5/36 | UGR2 | |
A61P 5/38 | UGR1 | . | of the suprarenal hormones [7] |
|
A61P 5/40 | UGR2 | . . | Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids [7] |
|
A61P 5/42 | UGR2 | . . | for decreasing, blocking or antagonising the activity of mineralocorticosteroids [7] |
|
A61P 5/44 | UGR2 | . . | Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids [7] |
|
A61P 5/46 | UGR2 | . . | for decreasing, blocking or antagonising the activity of glucocorticosteroids [7] |
|
A61P 5/48 | UGR1 | . | of the pancreatic hormones [7] |
|
A61P 5/50 | UGR2 | . . | for increasing or potentiating the activity of insulin [7] |
|
A61P 7/00 | HGR | Drugs for disorders of the blood or the extracellular fluid [7] |
A61P 7/02 | UGR1 | . | Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors [7] |
|
A61P 7/04 | UGR1 | . | Antihaemorrhagics; Procoagulants; Haemostatatic agents; Antifibrinolytic agents [7] |
|
A61P 7/06 | UGR1 | |
A61P 7/08 | UGR1 | . | Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P 27/04) [7] |
|
A61P 7/10 | UGR1 | . | Antioedematous agents; Diuretics [7] |
|
A61P 7/12 | UGR1 | . | Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P 5/10) [7] |
|
A61P 9/00 | HGR | Drugs for disorders of the cardiovascular system [7] |
A61P 9/02 | UGR1 | . | Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives [7] |
|
A61P 9/04 | UGR1 | . | Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure [7] |
|
A61P 9/06 | UGR1 | |
A61P 9/08 | UGR1 | . | Vasodilators for multiple indications [7] |
|
A61P 9/10 | UGR1 | . | for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis [7] |
|
A61P 9/12 | UGR1 | |
A61P 9/14 | UGR1 | . | Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers [7] |
|
A61P 11/00 | HGR | Drugs for disorders of the respiratory system [7] |
A61P 11/02 | UGR1 | . | Nasal agents, e.g. decongestants [7] |
|
A61P 11/04 | UGR1 | . | for throat disorders [7] |
|
A61P 11/06 | UGR1 | |
A61P 11/08 | UGR1 | |
A61P 11/10 | UGR1 | |
A61P 11/12 | UGR1 | |
A61P 11/14 | UGR1 | |
A61P 11/16 | UGR1 | . | Central respiratory analeptics [7] |
|
A61P 13/00 | HGR | Drugs for disorders of the urinary system (diuretics A61P 7/10) [7] |
A61P 13/02 | UGR1 | . | of urine or of the urinary tract, e.g. urine acidifiers [7] |
|
A61P 13/04 | UGR1 | |
A61P 13/06 | UGR1 | |
A61P 13/08 | UGR1 | |
A61P 13/10 | UGR1 | |
A61P 13/12 | UGR1 | |
A61P 15/00 | HGR | Drugs for genital or sexual disorders (for disorders of sex hormones A61P 5/24); Contraceptives [7] |
A61P 15/02 | UGR1 | . | for disorders of the vagina [7] |
|
A61P 15/04 | UGR1 | . | for inducing labour or abortion; Uterotonics [7] |
|
A61P 15/06 | UGR1 | . | Antiabortive agents; Labour repressants [7] |
|
A61P 15/08 | UGR1 | . | for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis [7] |
|
A61P 15/10 | UGR1 | |
A61P 15/12 | UGR1 | . | for climacteric disorders [7] |
|
A61P 15/14 | UGR1 | . | for lactation disorders, e.g. galactorrhoea [7] |
|
A61P 15/16 | UGR1 | . | Masculine contraceptives [7] |
|
A61P 15/18 | UGR1 | . | Feminine contraceptives [7] |
|
A61P 17/00 | HGR | Drugs for dermatological disorders [7] |
A61P 17/02 | UGR1 | . | for treating wounds, ulcers, burns, scars, keloids, or the like [7] |
|
A61P 17/04 | UGR1 | |
A61P 17/06 | UGR1 | |
A61P 17/08 | UGR1 | |
A61P 17/10 | UGR1 | |
A61P 17/12 | UGR1 | . | Keratolytics, e.g. wart or anti-corn preparations [7] |
|
A61P 17/14 | UGR1 | . | for baldness or alopecia [7] |
|
A61P 17/16 | UGR1 | . | Emollients or protectives, e.g. against radiation [7] |
|
A61P 19/00 | HGR | Drugs for skeletal disorders [7] |
A61P 19/02 | UGR1 | . | for joint disorders, e.g. arthritis, arthrosis [7] |
|
A61P 19/04 | UGR1 | . | for non-specific disorders of the connective tissue [7] |
|
A61P 19/06 | UGR1 | . | Antigout agents, e.g. antihyperuricemic or uricosuric agents [7] |
|
A61P 19/08 | UGR1 | . | for bone diseases, e.g. rachitism, Paget's disease [7] |
|
A61P 19/10 | UGR2 | |
A61P 21/00 | HGR | Drugs for disorders of the muscular or neuromuscular system [7] |
A61P 21/02 | UGR1 | . | Muscle relaxants, e.g. for tetanus or cramps [7] |
|
A61P 21/04 | UGR1 | . | for myasthenia gravis [7] |
|
A61P 21/06 | UGR1 | |
A61P 23/00 | HGR | Anaesthetics [7] |
A61P 23/02 | UGR1 | |
A61P 25/00 | HGR | Drugs for disorders of the nervous system [7] |
A61P 25/02 | UGR1 | . | for peripheral neuropathies [7] |
|
A61P 25/04 | UGR1 | . | Centrally acting analgesics, e.g. opioids [7] |
|
A61P 25/06 | UGR1 | |
A61P 25/08 | UGR1 | . | Antiepileptics; Anticonvulsants [7] |
|
A61P 25/10 | UGR2 | |
A61P 25/12 | UGR2 | |
A61P 25/14 | UGR1 | . | for treating abnormal movements, e.g. chorea, dyskinesia [7] |
|
A61P 25/16 | UGR2 | . . | Anti-Parkinson drugs [7] |
|
A61P 25/18 | UGR1 | . | Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia [7] |
|
A61P 25/20 | UGR1 | . | Hypnotics; Sedatives [7] |
|
A61P 25/22 | UGR1 | |
A61P 25/24 | UGR1 | |
A61P 25/26 | UGR1 | . | Psychostimulants, e.g. nicotine, cocaine [7] |
|
A61P 25/28 | UGR1 | . | for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia [7] |
|
A61P 25/30 | UGR1 | . | for treating abuse or dependence [7] |
|
A61P 25/32 | UGR2 | |
A61P 25/34 | UGR2 | |
A61P 25/36 | UGR2 | |
A61P 27/00 | HGR | Drugs for disorders of the senses [7] |
A61P 27/02 | UGR1 | |
A61P 27/04 | UGR2 | . . | Artificial tears; Irrigation solutions [7] |
|
A61P 27/06 | UGR2 | . . | Antiglaucoma agents or miotics [7] |
|
A61P 27/08 | UGR2 | . . | Mydriatics or cycloplegics [7] |
|
A61P 27/10 | UGR2 | . . | for accommodation disorders, e.g. myopia [7] |
|
A61P 27/12 | UGR2 | |
A61P 27/14 | UGR2 | . . | Decongestants or antiallergics [7] |
|
A61P 27/16 | UGR1 | |
A61P 29/00 | HGR | Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs) [7] |
A61P 29/02 | UGR1 | . | without antiinflammatory effect [7] |
|
A61P 31/00 | HGR | Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics [7] |
A61P 31/02 | UGR1 | |
A61P 31/04 | UGR1 | . | Antibacterial agents [7] |
|
A61P 31/06 | UGR2 | |
A61P 31/08 | UGR2 | |
A61P 31/10 | UGR1 | |
A61P 31/12 | UGR1 | |
A61P 31/14 | UGR2 | |
A61P 31/16 | UGR3 | . . . | for influenza or rhinoviruses [7] |
|
A61P 31/18 | UGR3 | |
A61P 31/20 | UGR2 | |
A61P 31/22 | UGR3 | . . . | for herpes viruses [7] |
|
A61P 33/00 | HGR | Antiparasitic agents [7] |
A61P 33/02 | UGR1 | . | Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis [7] |
|
A61P 33/04 | UGR2 | |
A61P 33/06 | UGR2 | |
A61P 33/08 | UGR2 | . . | for Pneumocystis carinii [7] |
|
A61P 33/10 | UGR1 | |
A61P 33/12 | UGR2 | |
A61P 33/14 | UGR1 | . | Ectoparasiticides, e.g. scabicides [7] |
|
A61P 35/00 | HGR | Antineoplastic agents [7] |
A61P 35/02 | UGR1 | . | specific for leukemia [7] |
|
A61P 35/04 | UGR1 | . | specific for metastasis [7] |
|
A61P 37/00 | HGR | Drugs for immunological or allergic disorders [7] |
A61P 37/02 | UGR1 | |
A61P 37/04 | UGR2 | |
A61P 37/06 | UGR2 | . . | Immunosuppressants, e.g. drugs for graft rejection [7] |
|
A61P 37/08 | UGR1 | |
A61P 39/00 | HGR | General protective or antinoxious agents [7] |
A61P 39/02 | UGR1 | |
A61P 39/04 | UGR1 | |
A61P 39/06 | UGR1 | . | Free radical scavengers or antioxidants [7] |
|
A61P 41/00 | HGR | Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution [7] |
A61P 43/00 | HGR | Drugs for specific purposes, not provided for in groups A61P 1/00 to A61P 41/00 [7] |